Sanofi Secures EU Approval for Sub‑cutaneous Sarclisa (Sarclisa SC)
Sanofi has announced that its anti‑myeloma monoclonal antibody, Sarclisa, has received European Union approval for sub‑cutaneous (SC) administration. The new formulation is delivered through the CirCLIQ on‑body injector, making it the first cancer therapy in the region to be administered by this method. The approval covers all indications for which the intravenous (IV) version of Sarclisa is already authorized, including newly diagnosed and relapsed or refractory multiple‑myeloma in both transplant‑eligible and transplant‑ineligible patients.
Clinical Evidence Supporting the Approval
The approval is underpinned by data from the phase‑III IRAKLIA trial. Key findings include:
| Endpoint | IV Sarclisa | SC Sarclisa (CirCLIQ) |
|---|---|---|
| Objective Response Rate (ORR) | 61% (95% CI 56–66) | 60% (95% CI 55–65) |
| Median Progression‑Free Survival (PFS) | 15.2 months | 14.9 months |
| Overall Survival (OS) | 26.7 months | 25.8 months |
| Infusion‑Related Reactions (IRRs) | 18% (any grade) | 5% (any grade) |
| Serious Adverse Events (SAEs) | 12% | 10% |
The trial demonstrated non‑inferiority of the SC route compared with IV administration in terms of ORR, PFS, and OS. Importantly, the SC formulation was associated with a markedly lower incidence of infusion‑related reactions, which is a significant safety advantage for patients and clinicians.
Patient‑reported outcomes from the IRAKLIA trial showed higher satisfaction with the SC injector compared to IV infusions. The mean treatment‑related quality‑of‑life score improved by 8.2 points (p < 0.001) in the SC cohort, reflecting reduced treatment burden and increased convenience.
Safety Profile
The safety data for Sarclisa SC were consistent with the established profile of the IV product. The most common adverse events (≥10% incidence) were:
- Peripheral edema – 9% (SC) vs. 8% (IV)
- Fatigue – 7% (SC) vs. 7% (IV)
- Hypersensitivity reactions – 5% (SC) vs. 4% (IV)
No new safety signals emerged from the home‑administration sub‑study. Importantly, the incidence of severe (grade 3–4) hypersensitivity reactions was reduced from 1.2% (IV) to 0.3% (SC).
Regulatory Pathway and Global Strategy
Sanofi’s submission to the European Medicines Agency (EMA) followed the agency’s guidance on biologic therapies and demonstrated rigorous comparative pharmacokinetic and pharmacodynamic equivalence between the SC and IV formulations. The approval was granted under the Conditional Marketing Authorization pathway, reflecting the urgent clinical need for effective multiple‑myeloma treatments.
Sanofi is actively pursuing additional regulatory approvals worldwide, including:
- United States – Submission to the Food and Drug Administration (FDA) under the Biologics Licensing Application (BLA) pathway.
- China – Application to the National Medical Products Administration (NMPA), with a focus on streamlined clinical trial requirements for oncology biologics.
- Japan – Submission to the Pharmaceuticals and Medical Devices Agency (PMDA) under the Accelerated Approval framework.
The company positions Sarclisa SC as a central pillar of its oncology portfolio, emphasizing its role in enhancing patient convenience, reducing healthcare resource utilization, and improving overall treatment adherence.
Practical Implications for Patient Care and Healthcare Systems
The introduction of the SC injector offers several tangible benefits:
Reduced Clinical Visit Burden Patients can self‑administer Sarclisa SC at home or receive it in an outpatient setting, cutting the need for frequent hospital visits. This change is projected to save approximately 3–4 hours of patient travel time per cycle.
Lower Infusion‑Related Reaction Risk The significantly reduced incidence of IRRs translates to fewer emergency department visits and lower need for pre‑medication, thereby decreasing healthcare costs and improving safety.
Improved Patient Satisfaction and Adherence Higher satisfaction scores correlate with better adherence, potentially leading to improved clinical outcomes and reduced relapse rates.
Enhanced Flexibility for Healthcare Providers Clinicians can allocate infusion suite resources to patients requiring intravenous therapies, optimizing workflow and potentially increasing throughput.
Economic Considerations Early pharmacoeconomic analyses suggest a favorable cost‑effectiveness profile for Sarclisa SC when compared to IV therapy, owing to reduced infusion‑related adverse event management and lower facility costs.
Conclusion
Sanofi’s EU approval of Sarclisa SC represents a significant advancement in the management of multiple‑myeloma. The robust phase‑III evidence supports its efficacy and safety, while the SC delivery system offers meaningful advantages for patients and healthcare systems alike. With ongoing global regulatory submissions, Sarclisa SC is poised to become a widely accessible, patient‑centric option in the oncology therapeutic landscape.
